210 related articles for article (PubMed ID: 25742181)
1. A hypoxia efficient imidazole-based Ru(II) arene anticancer agent resistant to deactivation by glutathione.
Purkait K; Karmakar S; Bhattacharyya S; Chatterjee S; Dey SK; Mukherjee A
Dalton Trans; 2015 Apr; 44(13):5969-73. PubMed ID: 25742181
[TBL] [Abstract][Full Text] [Related]
2. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
[TBL] [Abstract][Full Text] [Related]
3. Alteration of steric hindrance modulates glutathione resistance and cytotoxicity of three structurally related Ru(II)-p-cymene complexes.
Purkait K; Chatterjee S; Karmakar S; Mukherjee A
Dalton Trans; 2016 May; 45(20):8541-55. PubMed ID: 27120485
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, characterization and biological evaluation of novel Ru(II)-arene complexes containing intercalating ligands.
Nikolić S; Rangasamy L; Gligorijević N; Aranđelović S; Radulović S; Gasser G; Grgurić-Šipka S
J Inorg Biochem; 2016 Jul; 160():156-65. PubMed ID: 26818702
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic Ru
Sarkar A; Acharya S; Khushvant K; Purkait K; Mukherjee A
Dalton Trans; 2019 May; 48(21):7187-7197. PubMed ID: 30601545
[TBL] [Abstract][Full Text] [Related]
6. Dinuclear [{(p-cym)RuCl}2(μ-phpy)](PF6)2 and heterodinuclear [(ppy)2Ir(μ-phpy)Ru(p-cym)Cl](PF6)2 complexes: synthesis, structure and anticancer activity.
Tripathy SK; De U; Dehury N; Pal S; Kim HS; Patra S
Dalton Trans; 2014 Oct; 43(39):14546-9. PubMed ID: 25160655
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia efficient and glutathione-resistant cytoselective ruthenium(II)-
Mondal A; Paira P
Dalton Trans; 2020 Sep; 49(36):12865-12878. PubMed ID: 32909559
[TBL] [Abstract][Full Text] [Related]
8. Cationic arene ruthenium(II) complexes with chelating P-functionalized alkyl phenyl sulfide and sulfoxide ligands as potent anticancer agents.
Ludwig G; Kaluđerović GN; Rüffer T; Bette M; Korb M; Block M; Paschke R; Lang H; Steinborn D
Dalton Trans; 2013 Mar; 42(11):3771-4. PubMed ID: 23340605
[TBL] [Abstract][Full Text] [Related]
9. Highly Cytotoxic Ruthenium(II)-Arene Complexes from Bulky 1-Pyrenylphosphane Ligands.
Brissos RF; Clavero P; Gallen A; Grabulosa A; Barrios LA; Caballero AB; Korrodi-Gregório L; Pérez-Tomás R; Muller G; Soto-Cerrato V; Gamez P
Inorg Chem; 2018 Dec; 57(23):14786-14797. PubMed ID: 30444630
[TBL] [Abstract][Full Text] [Related]
10. Strong Influence of Ancillary Ligands Containing Benzothiazole or Benzimidazole Rings on Cytotoxicity and Photoactivation of Ru(II) Arene Complexes.
Lari M; Martínez-Alonso M; Busto N; Manzano BR; Rodríguez AM; Acuña MI; Domínguez F; Albasanz JL; Leal JM; Espino G; García B
Inorg Chem; 2018 Nov; 57(22):14322-14336. PubMed ID: 30379535
[TBL] [Abstract][Full Text] [Related]
11. Effect of
Mukherjee A; Acharya S; Purkait K; Chakraborty K; Bhattacharjee A; Mukherjee A
Inorg Chem; 2020 May; 59(9):6581-6594. PubMed ID: 32295347
[TBL] [Abstract][Full Text] [Related]
12. Pyrazole appended quinoline-BODIPY based arene ruthenium complexes: their anticancer activity and potential applications in cellular imaging.
Paitandi RP; Sharma V; Singh VD; Dwivedi BK; Mobin SM; Pandey DS
Dalton Trans; 2018 Dec; 47(48):17500-17514. PubMed ID: 30507985
[TBL] [Abstract][Full Text] [Related]
13. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
[TBL] [Abstract][Full Text] [Related]
14. Ruthenium(II) polypyridyl complexes: cellular uptake, cell image and apoptosis of HeLa cancer cells induced by double targets.
Yu Q; Liu Y; Xu L; Zheng C; Le F; Qin X; Liu Y; Liu J
Eur J Med Chem; 2014 Jul; 82():82-95. PubMed ID: 24878637
[TBL] [Abstract][Full Text] [Related]
15. Self-assembled ruthenium (II) metallacycles and metallacages with imidazole-based ligands and their in vitro anticancer activity.
Zhao Y; Zhang L; Li X; Shi Y; Ding R; Teng M; Zhang P; Cao C; Stang PJ
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4090-4098. PubMed ID: 30765514
[TBL] [Abstract][Full Text] [Related]
16. Imine-N-Heterocyclic Carbenes as Versatile Ligands in Ruthenium(II) p-Cymene Anticancer Complexes: A Structure-Activity Relationship Study.
Yang Y; Guo L; Tian Z; Liu X; Gong Y; Zheng H; Ge X; Liu Z
Chem Asian J; 2018 Oct; 13(19):2923-2933. PubMed ID: 30101417
[TBL] [Abstract][Full Text] [Related]
17. Reversible pH-Responsive Behavior of Ruthenium(II) Arene Complexes with Tethered Carboxylate.
Martínez-Peña F; Infante-Tadeo S; Habtemariam A; Pizarro AM
Inorg Chem; 2018 May; 57(9):5657-5668. PubMed ID: 29688005
[TBL] [Abstract][Full Text] [Related]
18. Combining [arene-Ru] with azocarboxamide to generate a complex with cytotoxic properties.
Sommer MG; Kureljak P; Urankar D; Schweinfurth D; Stojanović N; Bubrin M; Gazvoda M; Osmak M; Sarkar B; Košmrlj J
Chemistry; 2014 Dec; 20(52):17296-9. PubMed ID: 25376425
[TBL] [Abstract][Full Text] [Related]
19. 3-Hydroxyflavones vs. 3-hydroxyquinolinones: structure-activity relationships and stability studies on Ru(II)(arene) anticancer complexes with biologically active ligands.
Kurzwernhart A; Kandioller W; Enyedy ÉA; Novak M; Jakupec MA; Keppler BK; Hartinger CG
Dalton Trans; 2013 May; 42(17):6193-202. PubMed ID: 23168616
[TBL] [Abstract][Full Text] [Related]
20. Piano-Stool Ruthenium(II) Complexes with Delayed Cytotoxic Activity: Origin of the Lag Time.
Rafols L; Josa D; Aguilà D; Barrios LA; Roubeau O; Cirera J; Soto-Cerrato V; Pérez-Tomás R; Martínez M; Grabulosa A; Gamez P
Inorg Chem; 2021 Jun; 60(11):7974-7990. PubMed ID: 33979132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
